Welcome to our dedicated page for Dyne Therapeutics SEC filings (Ticker: DYN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dyne Therapeutics, Inc. filings document regulatory disclosures for a clinical-stage neuromuscular disease company advancing FORCE platform programs. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary cash-resource disclosures, investor presentation materials, clinical and FDA-related updates, and other business highlights tied to Duchenne muscular dystrophy and myotonic dystrophy type 1 programs.
The company’s definitive proxy materials cover board structure, director elections, executive compensation, equity awards, stockholder voting matters and governance practices. Other filings address board appointments, non-employee director compensation arrangements and Nasdaq-related inducement equity awards.
Dyne Therapeutics, Inc. director-associated investment funds reported open-market sales of an aggregate 227,337 shares of Common Stock on April 28, 2026. The trades were executed at weighted-average prices around $18.38–$19.00 per share under a pre-arranged Rule 10b5-1 trading plan.
The shares are held through Atlas Venture-affiliated funds and partnerships, and the reporting person disclaims Section 16 beneficial ownership beyond any pecuniary interest. Following these transactions, the entities continue to hold large positions, including 4,939,489 shares in one fund and other seven-figure stakes in additional Atlas vehicles.
Dyne Therapeutics, Inc. director David Charles Lubner reported a bona fide gift of 53,625 shares of Common Stock on April 24, 2026. The transfer was recorded at $0.00 per share, and his directly owned holdings of this stock are now reported as 0 shares following the gift.